243 related articles for article (PubMed ID: 25966280)
1. AXL is an oncotarget in human colorectal cancer.
Martinelli E; Martini G; Cardone C; Troiani T; Liguori G; Vitagliano D; Napolitano S; Morgillo F; Rinaldi B; Melillo RM; Liotti F; Nappi A; Bianco R; Berrino L; Ciuffreda LP; Ciardiello D; Iaffaioli V; Botti G; Ferraiolo F; Ciardiello F
Oncotarget; 2015 Sep; 6(27):23281-96. PubMed ID: 25966280
[TBL] [Abstract][Full Text] [Related]
2. TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Schmitz R; Valls AF; Yerbes R; von Richter S; Kahlert C; Loges S; Weitz J; Schneider M; Ruiz de Almodovar C; Ulrich A; Schmidt T
Oncotarget; 2016 Aug; 7(35):56355-56370. PubMed ID: 27486820
[TBL] [Abstract][Full Text] [Related]
3. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.
Dantas-Barbosa C; Lesluyes T; Loarer FL; Chibon F; Treilleux I; Coindre JM; Meeus P; Brahmi M; Bally O; Ray-Coquard I; Sunyach MP; Cesne AL; Mir O; Bonvalot S; Toulmonde M; Italiano A; Saintigny P; Jean-Denis M; Ducimetiere F; Ranchere D; El Sayadi H; Alberti L; Blay JY
Br J Cancer; 2017 Dec; 117(12):1787-1797. PubMed ID: 29024938
[TBL] [Abstract][Full Text] [Related]
4. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.
Avilla E; Guarino V; Visciano C; Liotti F; Svelto M; Krishnamoorthy G; Franco R; Melillo RM
Cancer Res; 2011 Mar; 71(5):1792-804. PubMed ID: 21343401
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
[TBL] [Abstract][Full Text] [Related]
6. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
7. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
8. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
[TBL] [Abstract][Full Text] [Related]
9. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
11. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
[TBL] [Abstract][Full Text] [Related]
13. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
[TBL] [Abstract][Full Text] [Related]
14. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Gustafsson A; Fritz HKM; Dahlbäck B
Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
[TBL] [Abstract][Full Text] [Related]
15. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
16. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
17. In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling.
Peter SC; Mannu J; Mathur PP
Methods Mol Biol; 2017; 1549():221-229. PubMed ID: 27975295
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma.
Hattori S; Kikuchi E; Kosaka T; Miyazaki Y; Tanaka N; Miyajima A; Mikami S; Oya M
Ann Surg Oncol; 2016 Feb; 23(2):663-70. PubMed ID: 26350366
[TBL] [Abstract][Full Text] [Related]
20. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs.
Huang M; Chen M; Qi M; Ye G; Pan J; Shi C; Yang Y; Zhao L; Mo X; Zhang Y; Li Y; Zhong J; Lu W; Li X; Zhang J; Lin J; Luo L; Liu T; Tang PM; Hong A; Cao Y; Ye W; Zhang D
J Extracell Vesicles; 2021 May; 10(7):e12096. PubMed ID: 34035882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
